Citation: Donghu Yu, Junneng Wang, Lei Hu, Youxian Wu, Tianqing Wang, Zhiyu Li, Zefen Wang, Qihang Ding, Yao Sun, Zhiqiang Li. Knowledge structures and research hotspots of immunotherapy for brain metastasis, glioma, meningioma, and pituitary adenoma: A bibliometric and visualization review[J]. Chinese Chemical Letters, ;2025, 36(12): 110995. doi: 10.1016/j.cclet.2025.110995 shu

Knowledge structures and research hotspots of immunotherapy for brain metastasis, glioma, meningioma, and pituitary adenoma: A bibliometric and visualization review

Donghu Yu ^{a, 1} ,
Junneng Wang ^{a, 1} ,
Lei Hu ^{a, 1} ,
Youxian Wu ^a ,
Tianqing Wang ^a ,
Zhiyu Li ^a ,
Zefen Wang ^{b, *,} ,
Qihang Ding ^{c, *,} ,
Yao Sun ^{d, *,} ,
Zhiqiang Li ^{a, *,}

a.
Brain Glioma Center & Department of Neurosurgery, International Science and Technology Cooperation Base for Research and Clinical Techniques for Brain Glioma Diagnosis and Treatment, Zhongnan Hospital of Wuhan University, Wuhan 430071, China
b.
Department of Physiology, Wuhan University School of Basic Medical Sciences, Wuhan 430071, China
c.
Department of Chemistry, Korea University, Seoul 02841, South Korea
d.
National Key Laboratory of Green Pesticide, International Joint Research Center for Intelligent Biosensor Technology and Health, College of Chemistry, Central China Normal University, Wuhan 430079, China

wangzf@whu.edu.cn

dingqihang@whu.edu.cn

sunyaogbasp@mail.ccnu.edu.cn

lizhiqiang@whu.edu.cn

Received Date: 4 November 2024
Revised Date: 19 February 2025
Accepted Date: 21 February 2025
Available Online: 21 February 2025

Figures(4)

Recent insights into the immune landscape of the brain tumor microenvironment shed new light on immunotherapy for various brain tumors. This study provides comprehensive overviews of the development trends of immunotherapy for four common brain tumors (brain metastasis, glioma, meningioma, and pituitary adenoma), for which immunotherapy-related clinical trials have been conducted. Publications spanning from January 1, 2011, to December 31, 2023, were retrieved from the Web of Science Core Collection for a bibliometric analysis aimed at visualizing research trends and hotspots in immunotherapy for brain metastases, gliomas, meningiomas, and pituitary adenomas. Additionally, ongoing clinical trials were reviewed to identify the frontiers of immunotherapy in brain tumors. Research activity has significantly increased for brain metastasis and glioma, while studies on meningioma and pituitary adenoma remain in the nascent stages. The United States and China are the leading countries in these four research areas. Keyword analysis and ongoing trials underscore the crucial role of immune checkpoint inhibitors, which are currently a focal point in the treatment of various brain tumors. This review outlines the knowledge structures and research priorities in immunotherapy over the past 13 years, providing valuable insights for researchers in these fields.
- Immunotherapy,
- Brain tumors,
- Bibliometric analysis,
- Clinical trials,
- Immune checkpoint inhibitors
1. [1]
  P. Sharma, B.A. Siddiqui, S. Anandhan, et al., Cancer Discov. 11 (2021) 838–857. doi: 10.1158/2159-8290.cd-20-1680
2. [2]
  A.D. Waldman, J.M. Fritz, M.J. Lenardo, Nat. Rev. Immunol. 20 (2020) 651–668. doi: 10.1038/s41577-020-0306-5
3. [3]
  C. Garbe, R. Dummer, T. Amaral, et al., Nat. Med. 29 (2023) 1310–1312. doi: 10.1038/s41591-023-02336-1
4. [4]
  A.C. Huang, R. Zappasodi, Nat. Immunol. 23 (2022) 660–670. doi: 10.1038/s41590-022-01141-1
5. [5]
  G. Casirati, A. Cosentino, A. Mucci, et al., Nature 621 (2023) 404–414. doi: 10.1038/s41586-023-06496-5
6. [6]
  L. Tang, Z. Huang, H. Mei, Y. Hu, Signal. Transduct. Target. Ther. 8 (2023) 306. doi: 10.1038/s41392-023-01521-5
7. [7]
  J.G. Lyon, N. Mokarram, T. Saxena, S.L. Carroll, R.V. Bellamkonda, Adv. Drug Deliv. Rev. 114 (2017) 19–32. doi: 10.1016/j.addr.2017.06.006
8. [8]
  A. Sabbagh, K. Beccaria, X. Ling, et al., Clin. Cancer Res. 27 (2021) 4325–4337. doi: 10.1158/1078-0432.ccr-20-3760
9. [9]
  F. Bai, Y. Deng, L. Li, et al., Exploration 4 (2024) 20230177. doi: 10.1002/EXP.20230177
10. [10]
  A. Zhang, K. Miao, H. Sun, C.X. Deng, Int. J. Biol. Sci. 18 (2022) 3019–3033. doi: 10.7150/ijbs.72534
11. [11]
  A. Ahmad, P. Khan, A.U. Rehman, S.K. Batra, M.W. Nasser, Mol. Cancer 22 (2023) 111. doi: 10.1186/s12943-023-01818-7
12. [12]
  J.H. Suh, R. Kotecha, S.T. Chao, et al., Nat. Rev. Clin. Oncol. 17 (2020) 279–299. doi: 10.1038/s41571-019-0320-3
13. [13]
  A.M. Di Giacomo, M. Valente, A. Cerase, et al., J. Exp. Clin. Cancer Res. 38 (2019) 419. doi: 10.1186/s13046-019-1426-2
14. [14]
  P.K.K. Brastianos, A.E.E. Kim, A. Giobbie-Hurder, et al., Nat. Med. 29 (2023) 1728. doi: 10.1038/s41591-023-02392-7
15. [15]
  E. Nieblas-Bedolla, N. Nayyar, M. Singh, R.J. Sullivan, P.K. Brastianos, Oncologist 26 (2021) 231–241. doi: 10.1002/onco.13575
16. [16]
  K.J. Habashy, R. Mansour, C. Moussalem, R. Sawaya, M.J. Massaad, Br. J. Cancer 127 (2022) 976–987. doi: 10.1038/s41416-022-01864-w
17. [17]
  D.N. Louis, A. Perry, P. Wesseling, et al., Neuro Oncol. 23 (2021) 1231–1251. doi: 10.1093/neuonc/noab106
18. [18]
  T.F. Cloughesy, A.Y. Mochizuki, J.R. Orpilla, et al., Nat. Med. 25 (2019) 477. doi: 10.1038/s41591-018-0337-7
19. [19]
  K.A. Schalper, M.E. Rodriguez-Ruiz, R. Diez-Valle, et al., Nat. Med. 25 (2019) 470. doi: 10.1038/s41591-018-0339-5
20. [20]
  Q.T. Ostrom, M. Price, C. Neff, et al., Neuro Oncol. 24 (2022) v1–v95. doi: 10.1093/neuonc/noac202
21. [21]
  J. Moliterno, W.P. Cope, E.D. Vartanian, et al., J. Neurosurg. 123 (2015) 23–30. doi: 10.3171/2014.10.JNS14502
22. [22]
  M. Terabe, J. Wu, Neuro Oncol. 23 (2021) 1812–1813. doi: 10.1093/neuonc/noab168
23. [23]
  G. Medici, L.K. Freudenmann, J. Velz, et al., Acta Neuropathol. 146 (2023) 173–190. doi: 10.1007/s00401-023-02605-w
24. [24]
  T. Feola, F. Carbonara, M. Verrico, et al., Cancers 14 (2022) 4093. doi: 10.3390/cancers14174093
25. [25]
  G. Raverot, M.D. Ilie, H. Lasolle, et al., Nat. Rev. Endocrinol. 17 (2021) 671–684. doi: 10.1038/s41574-021-00550-w
26. [26]
  C. Dai, S. Liang, B. Sun, J. Kang, Front. Endocrinol. 11 (2020) 608422. doi: 10.3389/fendo.2020.608422
27. [27]
  Y. Mei, W.L. Bi, N.F. Greenwald, et al., Oncotarget 7 (2016) 76565–76576. doi: 10.18632/oncotarget.12088
28. [28]
  Y.D. Miao, W. Quan, X. Dong, et al., Cell. Death. Discov. 9 (2023) 129. doi: 10.1038/s41420-023-01421-1
29. [29]
  S.E.H. Zyoud, S.W. Al-Jabi, R. Amer, et al., J. Transl. Med. 20 (2022) 83. doi: 10.1186/s12967-022-03293-y
30. [30]
  Z. Shen, J. Hu, H. Wu, et al., J. Transl. Med. 20 (2022) 409. doi: 10.1186/s12967-022-03615-0
31. [31]
  J. Jin, Y. Wan, Q. Shu, J. Liu, D. Lai, Front. Immunol. 14 (2023) 1158323. doi: 10.3389/fimmu.2023.1158323
32. [32]
  M. Aria, C. Cuccurullo, J. Informetrics 11 (2017) 959–975. doi: 10.1016/j.joi.2017.08.007
33. [33]
  N.J. van Eck, L. Waltman, Scientometrics 84 (2010) 523–538. doi: 10.1007/s11192-009-0146-3
34. [34]
  S.B. Goldberg, S.N. Gettinger, A. Mahajan, et al., Lancet Oncol. 17 (2016) 976–983. doi: 10.1016/S1470-2045(16)30053-5
35. [35]
  C.E. Brown, D. Alizadeh, R. Starr, et al., N. Engl. J. Med. 375 (2016) 2561–2569. doi: 10.1056/NEJMoa1610497
36. [36]
  S.J. Han, G. Reis, G. Kohanbash, et al., J. Neuro Oncol. 130 (2016) 543–552. doi: 10.1007/s11060-016-2256-0
37. [37]
  J.H. Sampson, M.D. Gunn, P.E. Fecci, D.M. Ashley, Nat. Rev. Cancer 20 (2020) 12–25. doi: 10.1038/s41568-019-0224-7
38. [38]
  J.D. Bernstock, K.D. Kang, N.V. Klinger, et al., Oncogene 41 (2022) 2663–2671. doi: 10.1038/s41388-022-02312-y
39. [39]
  C.E. Brown, S. Bucktrout, L.H. Butterfield, et al., J. Transl. Med. 20 (2022) 236. doi: 10.1186/s12967-022-03438-z
40. [40]
  G.V. Long, V. Atkinson, S. Lo, et al., Lancet Oncol. 19 (2018) 672–681. doi: 10.1016/S1470-2045(18)30139-6
41. [41]
  H.M. Kluger, V. Chiang, A. Mahajan, et al., J. Clin. Oncol. 37 (2019) 52. doi: 10.1200/jco.18.00204
42. [42]
  H. Zhang, H. Yu, G. Zhao, et al., Front. Endocrinol. 14 (2023) 1273634. doi: 10.3389/fendo.2023.1273634
43. [43]
  Y. Yuan, Y. Su, Y. Wu, et al., Front. Oncol. 13 (2023) 1229905. doi: 10.3389/fonc.2023.1229905
44. [44]
  M. Lim, Y. Xia, C. Bettegowda, M. Weller, Nat. Rev. Clin. Oncol. 15 (2018) 422–442. doi: 10.1038/s41571-018-0003-5
45. [45]
  D.A. Reardon, A.A. Brandes, A. Omuro, et al., JAMA Oncol. 6 (2020) 1003–1010. doi: 10.1001/jamaoncol.2020.1024
46. [46]
  D.M. O'Rourke, M.P. Nasrallah, A. Desai, et al., Sci. Transl. Med. 9 (2017) eaaa0984. doi: 10.1126/scitranslmed.aaa0984
47. [47]
  M. Ding, A. Zhu, Y. Zhang, et al., Nano Today 57 (2024) 102398. doi: 10.1016/j.nantod.2024.102398
48. [48]
  H. Chen, T. Li, Z. Liu, et al., Nat. Commun. 14 (2023) 941. doi: 10.1038/s41467-022-35709-0
49. [49]
  T. Wang, H. Zhang, W. Qiu, et al., Bioact. Mater. 16 (2022) 418–432.
50. [50]
  D. Yu, M. Liu, Q. Ding, et al., Biomaterials 316 (2025) 123021. doi: 10.1016/j.biomaterials.2024.123021
51. [51]
  F. Ghiringhelli, C. Rebe, Immunol. Rev. 321 (2024) 335–349. doi: 10.1111/imr.13263
52. [52]
  L. Tu, C. Li, Q. Ding, et al., J. Am. Chem. Soc. 146 (2024) 8991–9003. doi: 10.1021/jacs.3c13224
53. [53]
  W.L. Bi, L. Nayak, D.M. Meredith, et al., Neuro Oncol. 24 (2022) 101–113. doi: 10.1093/neuonc/noab118
54. [54]
  M.D. Ilie, C. Villa, T. Cuny, et al., Eur. J. Endocrinol. 187 (2022) 685–696. doi: 10.1530/eje-22-0647
55. [55]
  Y. Zhang, Z. Zhang, Cell. Mol. Immunol. 17 (2020) 807–821. doi: 10.1038/s41423-020-0488-6
56. [56]
  L. Kraehenbuehl, C.H. Weng, S. Eghbali, J.D. Wolchok, T. Merghoub, Nat. Rev. Clin. Oncol. 19 (2022) 37–50. doi: 10.1038/s41571-021-00552-7
57. [57]
  A. Peri, N. Salomon, Y. Wolf, et al., Nat. Cancer 4 (2023) 937–954. doi: 10.1038/s43018-023-00588-x
58. [58]
  L.K. Donovan, M.D. Taylor, Cell Res. 32 (2022) 505–506. doi: 10.1038/s41422-022-00649-3
59. [59]
  K. Yang, A. Halima, T.A. Chan, Nat. Rev. Clin. Oncol. 20 (2023) 604–623. doi: 10.1038/s41571-023-00789-4
60. [60]
  M. Ramos-Casals, J.R. Brahmer, M.K. Callahan, et al., Nat. Rev. Dis. Primers 6 (2020) 38. doi: 10.1038/s41572-020-0160-6
61. [61]
  Q. Sun, Z. Hong, C. Zhang, et al., Signal Transduc. Target. Ther. 8 (2023) 320. doi: 10.1038/s41392-023-01522-4
62. [62]
  D.J. Baker, Z. Arany, J.A. Baur, J.A. Epstein, C.H. June, Nature 619 (2023) 707–715. doi: 10.1038/s41586-023-06243-w
63. [63]
  C.H. June, R.S. O'Connor, O.U. Kawalekar, S. Ghassemi, M.C. Milone, Science 359 (2018) 1361–1365. doi: 10.1126/science.aar6711
64. [64]
  K.M. Cappell, J.N. Kochenderfer, Nat. Rev. Clin. Oncol. 20 (2023) 359–371. doi: 10.1038/s41571-023-00754-1
65. [65]
  Y. Xie, X. Li, J. Wu, et al., Chin. Chem. Lett. 34 (2023) 108202. doi: 10.1016/j.cclet.2023.108202
66. [66]
  S.A. Rosenberg, J.C. Yang, N.P. Restifo, Nat. Med. 10 (2004) 909–915. doi: 10.1038/nm1100
67. [67]
  M.J. Lin, J. Svensson-Arvelund, G.S. Lubitz, et al., Nat. Cancer 3 (2022) 911–926. doi: 10.1038/s43018-022-00418-6
68. [68]
  J. Adamik, L.H. Butterfield, Sci. Transl. Med. 14 (2022) eabo4632. doi: 10.1126/scitranslmed.abo4632
69. [69]
  M. Tagliamonte, B. Cavalluzzo, A. Mauriello, et al., Mol. Cancer 22 (2023) 75. doi: 10.1186/s12943-023-01776-0
70. [70]
  D. Lin, Y. Shen, T. Liang, Signal Transduc. Target. Ther. 8 (2023) 156. doi: 10.1038/s41392-023-01407-6
71. [71]
  S.Z. Shalhout, D.M. Miller, K.S. Emerick, H.L. Kaufman, Nat. Rev. Clin. Oncol. 20 (2023) 160–177. doi: 10.1038/s41571-022-00719-w
72. [72]
  A.K. Park, Y. Fong, S.I. Kim, et al., Sci. Transl. Med. 12 (2020) eaaz1863. doi: 10.1126/scitranslmed.aaz1863
73. [73]
  C. Hajal, Y. Shin, L. Li, et al., Sci. Adv. 7 (2021) eabg8139. doi: 10.1126/sciadv.abg8139
74. [74]
  J.D. Hebert, J.W. Neal, M.M. Winslow, Nat. Rev. Cancer 23 (2023) 391–407. doi: 10.1038/s41568-023-00568-4
75. [75]
  T.K. Owonikoko, J. Arbiser, A. Zelnak, et al., Nat. Rev. Clin. Oncol. 11 (2014) 203–222. doi: 10.1038/nrclinonc.2014.25
76. [76]
  M.A. Davies, P. Liu, S. McIntyre, et al., Cancer 117 (2011) 1687–1696. doi: 10.1002/cncr.25634
77. [77]
  J.T. Moyers, E.G. Chong, J. Peng, et al., Cancer Med. 10 (2021) 1201–1211. doi: 10.1002/cam4.3716
78. [78]
  A. Lauko, R. Kotecha, A. Barnett, et al., Sci. Rep. 11 (2021) 18174. doi: 10.1038/s41598-021-97566-z
79. [79]
  S. Kang, H. Jeong, J.E. Park, et al., Ann. Oncol. 33 (2022) S1081–S1082.
80. [80]
  A. Le, H. Mohammadi, T. Mohammed, et al., J. Neuro Oncol. 158 (2022) 481–488. doi: 10.1007/s11060-022-04038-z
81. [81]
  V. Borzillo, R. Di Franco, D. Giannarelli, et al., Cancers 13 (2021) 1857. doi: 10.3390/cancers13081857
82. [82]
  T. Amaral, F. Kiecker, S. Schaefer, et al., J. Immunother. Cancer 8 (2020) e000333. doi: 10.1136/jitc-2019-000333
83. [83]
  I. Hadi, O. Roengvoraphoj, R. Bodensohn, et al., Radiat. Oncol. 15 (2020) 37. doi: 10.1186/s13014-020-1485-8
84. [84]
  J. Liermann, J.K. Winkler, M. Syed, et al., Front. Oncol. 10 (2020) 592796. doi: 10.3389/fonc.2020.592796
85. [85]
  T.L. Enright, J.S. Witt, A.R. Burr, et al., Clin. Lung Cancer 22 (2021) 110–119. doi: 10.1016/j.cllc.2020.10.014
86. [86]
  A. Cho, H. Untersteiner, D. Hirschmann, et al., Cancers 12 (2020) 3668. doi: 10.3390/cancers12123668
87. [87]
  S. Scoccianti, E. Olmetto, V. Pinzi, et al., Neuro-Oncol. 23 (2021) 1750–1764. doi: 10.1093/neuonc/noab129
88. [88]
  M. Abdulhaleem, H. Johnston, R. D'Agostino Jr., et al., J. Neuro-Oncol. 157 (2022) 101–107. doi: 10.1007/s11060-022-03951-7
89. [89]
  T. Amaral, I. Tampouri, T. Eigentler, et al., Immunotherapy 11 (2019) 297–309. doi: 10.2217/imt-2018-0149
90. [90]
  P.D. Banks, A. Lasocki, P.K.H. Lau, et al., Health. Sci. Rep. 2 (2019) e115. doi: 10.1002/hsr2.115
91. [91]
  Z. Ye, X. Ai, L. Zhao, et al., Oncogene 40 (2021) 6059–6070. doi: 10.1038/s41388-021-02010-1
92. [92]
  J.R.D. Pearson, T. Regad, Signal Transduct. Target. Ther. 2 (2017) 17040. doi: 10.1038/sigtrans.2017.40
93. [93]
  J.P. Lynes, A.K. Nwankwo, H.P. Sur, et al., J. Immunother. Cancer 8 (2020) e000348. doi: 10.1136/jitc-2019-000348
94. [94]
  D. Yu, Q. Zhong, Y. Xiao, et al., NPJ Precis. Oncol. 8 (2024) 140. doi: 10.1038/s41698-024-00632-8
95. [95]
  A. Rusak, B. Wiatrak, K. Krawczynska, et al., Transl. Oncol. 51 (2025) 102187. doi: 10.1016/j.tranon.2024.102187
96. [96]
  M. Vanneman, G. Dranoff, Nat. Rev. Cancer 12 (2012) 237–251. doi: 10.1038/nrc3237
97. [97]
  C.N. Baxevanis, A.D. Gritzapis, I.F. Voutsas, et al., Cancers 14 (2022) 2674. doi: 10.3390/cancers14112674
98. [98]
  Z. Zhang, X. Liu, D. Chen, J. Yu, Signal Transduct. Target. Ther. 7 (2022) 258. doi: 10.1038/s41392-022-01102-y
99. [99]
  D.S. Vinay, E.P. Ryan, G. Pawelec, et al., Semin. Cancer Biol. 35 (2015) S185–S198. doi: 10.1016/j.semcancer.2015.03.004
100. [100]
  A.S. Luksik, E. Yazigi, P. Shah, C.M. Jackson, Cancers 15 (2023) 1414. doi: 10.3390/cancers15051414
101. [101]
  S.I. Choi, J. Yin, Front. Immunol. 13 (2022) 1008751. doi: 10.3389/fimmu.2022.1008751
102. [102]
  G. Dagar, A. Gupta, T. Masoodi, et al., J. Transl. Med. 21 (2023) 449. doi: 10.1186/s12967-023-04292-3
103. [103]
  D.B. Keskin, A.J. Anandappa, J. Sun, et al., Nature 565 (2019) 234–239. doi: 10.1038/s41586-018-0792-9
104. [104]
  M. Weller, N. Butowski, D.D. Tran, et al., Lancet Oncol. 18 (2017) 1373–1385. doi: 10.1016/S1470-2045(17)30517-X
105. [105]
  B. Segura-Collar, S. Hiller-Vallina, O. de Dios, et al., Acta Neuropathol. Commun. 11 (2023) 79. doi: 10.1186/s40478-023-01569-y
106. [106]
  R.T. Merrell, P.Y. Wen, D.A. Forst, et al., J. Clin. Oncol. 42 (2024) TPS2100. doi: 10.1200/jco.2024.42.16_suppl.tps2100
107. [107]
  T. Todo, H. Ito, Y. Ino, et al., Nat. Med. 28 (2022) 1630–1639. doi: 10.1038/s41591-022-01897-x
108. [108]
  P. Liu, Y. Wang, Y. Wang, et al., Gene Ther. 29 (2022) 115–126. doi: 10.1038/s41434-020-00207-9
109. [109]
  Q. Zhang, F. Liu, Cell Death Dis. 11 (2020) 485. doi: 10.1038/s41419-020-2696-5
110. [110]
  N. Aldrak, S. Alsaab, A. Algethami, et al., Cells 10 (2021) 1541. doi: 10.3390/cells10061541
111. [111]
  N. Ji, D. Weng, C. Liu, et al., Oncotarget 7 (2016) 4369–4378. doi: 10.18632/oncotarget.6737
112. [112]
  A. Bianconi, G. Palmieri, G. Aruta, et al., Biomedicines 11 (2023) 1520. doi: 10.3390/biomedicines11061520
113. [113]
  Q.T. Ostrom, G. Cioffi, H. Gittleman, et al., Neuro Oncol. 21 (2019) V1–V100. doi: 10.1093/neuonc/noz150
114. [114]
  L. Rogers, I. Barani, M. Chamberlain, et al., J. Neurosurg. 122 (2015) 4–23. doi: 10.3171/2014.7.JNS131644
115. [115]
  T. Garzon-Muvdi, D.D. Bailey, M.N. Pernik, E. Pan, Front. Neurol. 11 (2020) 945. doi: 10.3389/fneur.2020.00945
116. [116]
  D.T. Proctor, Z. Patel, S. Lama, et al., Oncoimmunology 8 (2018) e1512943.
117. [117]
  E. Gelerstein, A. Berger, T. Jonas-Kimchi, et al., J. Clin. Neurosci. 37 (2017) 51–53. doi: 10.1016/j.jocn.2016.11.011
118. [118]
  I.E. Dunn, Z. Du, M. Touat, et al., JCO Precis. Oncology 2 (2018) 1–12. doi: 10.1200/po.18.00190
119. [119]
  P.H. Domingues, C. Teodosio, J. Ortiz, et al., Am. J. Pathol. 181 (2012) 1749–1761. doi: 10.1016/j.ajpath.2012.07.033
120. [120]
  L. Fang, D.E. Lowther, M.L. Meizlish, et al., Neuro Oncol. 15 (2013) 1479–1490. doi: 10.1093/neuonc/not110
121. [121]
  Y.D. Li, D. Veliceasa, J. Lamano, et al., Cancer Immunol. Immunother. 68 (2019) 999–1009. doi: 10.1007/s00262-019-02342-8
122. [122]
  M.E. Molitch, JAMA 317 (2017) 516–524. doi: 10.1001/jama.2016.19699
123. [123]
  T.M. Hansen, S. Batra, M. Lim, et al., Neurosurg. Rev. 37 (2014) 279–285. doi: 10.1007/s10143-014-0525-y
124. [124]
  L. Kasuki, G. Raverot, Rev. Endocrine Metab. Disord. 21 (2020) 203–208. doi: 10.1007/s11154-019-09531-x
125. [125]
  G. Raverot, P. Burman, A. McCormack, et al., Eur. J. Endocrinol. 178 (2018) G1–G24. doi: 10.1530/EJE-17-0796
126. [126]
  M.B.S. Lopes, Acta Neuropathol. 134 (2017) 521–535. doi: 10.1007/s00401-017-1769-8
127. [127]
  A.L. Lin, P. Jonsson, V. Tabar, et al., J. Clin. Endocrinol. Metab. 103 (2018) 3925–3930. doi: 10.1210/jc.2018-01347
128. [128]
  M. Caccese, M. Barbot, F. Ceccato, et al., Anticancer Drugs 31 (2020) 199–203. doi: 10.1097/cad.0000000000000856
1. [1]
  Bohan Chen , Liming Gong , Jing Feng , Mingji Jin , Liqing Chen , Zhonggao Gao , Wei Huang . Research advances of nanoparticles for CAR-T therapy in solid tumors. Chinese Chemical Letters, 2024, 35(9): 109432-. doi: 10.1016/j.cclet.2023.109432
2. [2]
  Meng Sun , Jiazhen Yang , Leijiao Li , Yunhui Li , Wenliang Li , Jianxun Ding . Engineered bacteria potentiate cancer immunotherapy. Chinese Chemical Letters, 2025, 36(9): 111093-. doi: 10.1016/j.cclet.2025.111093
3. [3]
  Liangliang Jia , Ye Hong , Xinyu He , Ying Zhou , Liujiao Ren , Hongjun Du , Bin Zhao , Bin Qin , Zhe Yang , Di Gao . Fighting hypoxia to improve photodynamic therapy-driven immunotherapy: Alleviating, exploiting and disregarding. Chinese Chemical Letters, 2025, 36(2): 109957-. doi: 10.1016/j.cclet.2024.109957
4. [4]
  Shuang Liang , Jianjun Yao , Dan Liu , Mengli Zhou , Yong Cui , Zhaohui Wang . Tumor-responsive covalent organic polymeric nanoparticles enhancing STING activation for cancer immunotherapy. Chinese Chemical Letters, 2025, 36(3): 109856-. doi: 10.1016/j.cclet.2024.109856
5. [5]
  Yuequan Wang , Congtian Wu , Chengcheng Feng , Qin Chen , Zhonggui He , Shenwu Zhang , Cong Luo , Jin Sun . Spatiotemporally-controlled supramolecular hybrid nanoassembly enabling ferroptosis-augmented photodynamic immunotherapy of cancer. Chinese Chemical Letters, 2025, 36(3): 109902-. doi: 10.1016/j.cclet.2024.109902
6. [6]
  Yanjun Cai , Yong Jiang , Yu Chen , Erzhuo Cheng , Yuan Gu , Yuwei Li , Qianqian Liu , Jian Zhang , Jifang Liu , Shisong Han , Bin Yang . Amplifying STING activation and immunogenic cell death by metal-polyphenol coordinated nanomedicines for enhanced cancer immunotherapy. Chinese Chemical Letters, 2025, 36(5): 110437-. doi: 10.1016/j.cclet.2024.110437
7. [7]
  Bo-Ran Chang , Lin Deng , Qing-Lian Wu , Wan-Qian Guo , Hui-Ying Xue . A review: Carbon-based materials as effective additives in anaerobic fermentation, focusing on microbial chain elongation and medium chain fatty acids production. Chinese Chemical Letters, 2025, 36(7): 110411-. doi: 10.1016/j.cclet.2024.110411
8. [8]
  Xinwen Li , Lili Li , Junqiu Jiang , Wangyang Mei , Zhaoxia Wang , Qingwei Gao , Huimin Zhou , Liangliang Wei , Qingliang Zhao . Seeking breakthroughs in advanced oxidation processes for waste activated sludge dewatering: A critical review of developments, bibliometrics and sustainable solutions. Chinese Chemical Letters, 2025, 36(11): 110847-. doi: 10.1016/j.cclet.2025.110847
9. [9]
  Chenlu Huang , Xinyu Yang , Qingyu Yu , Linhua Zhang , Dunwan Zhu . Gas-generating polymersomes-based amplified photoimmunotherapy for abscopal effect and tumor metastasis inhibition. Chinese Chemical Letters, 2024, 35(6): 109680-. doi: 10.1016/j.cclet.2024.109680
10. [10]
  Junjie Wang , Yan Wang , Zhengdong Li , Changqiang Xie , Musammir Khan , Xingzhou Peng , Fabiao Yu . Triphenylamine-AIEgens photoactive materials for cancer theranostics. Chinese Chemical Letters, 2024, 35(6): 108934-. doi: 10.1016/j.cclet.2023.108934
11. [11]
  Xinyue Lan , Junguang Liang , Churan Wen , Xiaolong Quan , Huimin Lin , Qinqin Xu , Peixian Chen , Guangyu Yao , Dan Zhou , Meng Yu . Photo-manipulated polyunsaturated fatty acid-doped liposomal hydrogel for flexible photoimmunotherapy. Chinese Chemical Letters, 2024, 35(4): 108616-. doi: 10.1016/j.cclet.2023.108616
12. [12]
  Jiechen Liu , Xiaoguang Li , Ruiyang Xia , Yuqi Wang , Fenghe Zhang , Yongzhi Pang , Qing Li . Efficient suppression of oral squamous cell carcinoma through spatial dimension conversion drug delivery systems-enabled immunomodulatory-photodynamic therapy. Chinese Chemical Letters, 2024, 35(12): 109619-. doi: 10.1016/j.cclet.2024.109619
13. [13]
  Xiaofang Luo , Ye Wu , Xiaokun Zhang , Min Tang , Feiye Ju , Zuodong Qin , Gregory J Duns , Wei-Dong Zhang , Jiang-Jiang Qin , Xin Luan . Peptide-based strategies for overcoming multidrug-resistance in cancer therapy. Chinese Chemical Letters, 2025, 36(1): 109724-. doi: 10.1016/j.cclet.2024.109724
14. [14]
  Weiqian Jin , Lin Liao , Tao Qin , Xiaoxuan Guan , Huyang Gao , Peng Liang , Ming Gao , Junyu Lu . Recent advances in nanomedicine therapy for bacterial pneumonia. Chinese Chemical Letters, 2025, 36(6): 110920-. doi: 10.1016/j.cclet.2025.110920
15. [15]
  Rongrong Zheng , Zuxiao Chen , Qiuyuan Li , Ni Yang , Wenjun Zhang , Chuyu Huang , Linping Zhao , Xin Chen , Hong Cheng , Shiying Li . Endoplasmic reticulum targeting photodynamic oxidizer to boost anti-tumor immunity by intensifying immunogenic cell death in conjunction with IDO1 inhibition. Chinese Chemical Letters, 2025, 36(12): 110865-. doi: 10.1016/j.cclet.2025.110865
16. [16]
  Kun Chen , Huimin Lin , Xin Peng , Ziying Wu , Jingyue Dai , Yi Sun , Yaxuan Feng , Ziyi Huang , Zhiqiang Yu , Meng Yu , Guangyu Yao , Jigang Wang . In situ synthesis of MnO₂ micro/nano-adjuvants for enhanced immunotherapy of breast tumors. Chinese Chemical Letters, 2025, 36(5): 110045-. doi: 10.1016/j.cclet.2024.110045
17. [17]
  Xue Zheng , Jizhen Xie , Xing Zhang , Weiting Sun , Heyang Zhao , Yantuan Li , Cheng Wang . Corrigendum to "An overview of polymeric nanomicelles in clinical trials and on the market" [Chinese Chemical Letters 32 (2021) 243-257]. Chinese Chemical Letters, 2025, 36(2): 110545-. doi: 10.1016/j.cclet.2024.110545
18. [18]
  Shuyu Liu , Xiaomin Sun , Bohan Song , Gaofeng Zeng , Bingbing Du , Chongshen Guo , Cong Wang , Lei Wang . Design and Fabrication of Phospholipid-Vesicle-based Artificial Cells towards Biomedical Applications. University Chemistry, 2024, 39(11): 182-188. doi: 10.12461/PKU.DXHX202404113
19. [19]
  Huijuan Zhang , Chenglin Liang , Xinyi Ding , Meng Zhang , Siyu Lu , Lin Hou . Manganese-based nano-delivery system for sensitized anti-tumor immunotherapy via combined autophagy inhibition. Chinese Chemical Letters, 2025, 36(7): 110525-. doi: 10.1016/j.cclet.2024.110525
20. [20]
  Qi Wei , Hua Xin , Xiaolong Wang , Changjuan Qin , Yuanzhen Su , Di Li , Jianxun Ding . Unimolecular chiral poly(amino acid)s as adjuvants of nanovaccines for augmented cancer immunotherapy. Chinese Chemical Letters, 2025, 36(11): 111477-. doi: 10.1016/j.cclet.2025.111477

Get Citation

PDF

XML

Metrics

PDF Downloads(0)
Abstract views(20)
HTML views(5)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142